Article

Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike…

medRxiv · 2022 · Miguel Ã. Muñoz-Alía, author Rebecca A. Nace, author Baskar Balakrishnan, author Lianwen Zhang, author Nandakumar Packiriswamy, author Gagandeep Singh, author Prajakta Warang, author Ignacio Mena, author Riya Narjari, author Rianna Vandergaast, author Adolfo García-Sastre, author Michael Schotsaert, author Stephen J. Russell, author

Key facts

Title Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.
First author Miguel Ã. Muñoz-Alía, author Rebecca A. Nace, author Baskar Balakrishnan, author Lianwen Zhang, author Nandakumar Packiriswamy, author Gagandeep Singh, author Prajakta Warang, author Ignacio Mena, author Riya Narjari, author Rianna Vandergaast, author Adolfo García-Sastre, author Michael Schotsaert, author Stephen J. Russell, author
Journal medRxiv
Published Dec 19, 2022
DOI 10.1101/2022.12.16.520799
Devices mentioned K802418, K822496, K850512, K850513, K850525, K964875, K973350, K990827
Product codes mentioned GQH, JIT, JLX, KIS, KIT, KQP, JJH, LXG, MVU, PFF, PFT

At a glance

  • 1–9 FDA submissions mentioned
  • 10–99 Product codes mentioned

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About Literature

Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.

Source: Publisher and PubMed metadata; device mentions identified by Orca1

Browse all Literature